<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00864318</url>
  </required_header>
  <id_info>
    <org_study_id>08 GENH 06</org_study_id>
    <nct_id>NCT00864318</nct_id>
  </id_info>
  <brief_title>Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis</brief_title>
  <acronym>TICE</acronym>
  <official_title>Dose Intensification Phase II Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis. TICE Protocol : Paclitaxel and Ifosfamide Followed by Carboplatine and Etoposide Intensification With Individual Carboplatine Dose Adjustment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Not randomized, multicentric, national phase II trial estimating the efficacy of an&#xD;
      intensification protocol in patients with refractory germ cell tumors with relapse and bad&#xD;
      prognosis.&#xD;
&#xD;
      Treatment consists in two Paclitaxel and Ifosfamide intensification cycles followed by three&#xD;
      Carboplatine and Etoposide high dose cycles. The point is the individual Carboplatine&#xD;
      adjustment to take into account inter-individual patients variability.&#xD;
&#xD;
      This adaptation allow to control each patient plasmatic exposition to avoid both inacceptable&#xD;
      toxicities (such as ear toxicity) and a low exposition losing then the benefit of this high&#xD;
      dose protocol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 13, 2009</start_date>
  <completion_date type="Actual">October 5, 2020</completion_date>
  <primary_completion_date type="Actual">October 5, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response rate(by chemotherapy or chemotherapy + surgery), pathological complete response rate.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To find a predictive value for Cystatin C as a biomarker of renal function to avoid next to follow plasmatic concentrations to adapt Carboplatine dose in TICE protocol.</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Etoposide pharmacokinetics (in particular inter-individual variability of Etoposide plasmatic concentrations AUC in such patients</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic polymorphisms involved in response and safety treatments</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">101</enrollment>
  <condition>Germ Cell Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>200mg/m2 for 3 hours at Cycle 1 day 1 and Cycle 2 day 1 with 14 days between cycles</description>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>2g/m²/day in 1 liter of G5 for 3 hours at Cycle 1 and Cycle 2 from day 2 to day 4 with 14 days between cycles</description>
    <other_name>Holoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatine</intervention_name>
    <description>From cycle 3 to cycle 5 :&#xD;
Carboplatine is administered with AUC = 24 mg/mL x min from Day 1 to Day 3. Day 3 Carboplatine dose is calculated taking into account real creatinine clearance defined at day 1 for each patient</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>From Cycle 3 to cycle 5, 400mg/m2/day from day 1 to day 3</description>
    <other_name>VP16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cytapheresis + transfusion of autologous peripheral blood stem cells</intervention_name>
    <description>Cytapheresis occured between day 11 and day 13 of the 2 first cycle (Taxol® +Holoxan®). Cytapheresis total objective is 9X106 CD34+/kg of patient weight.&#xD;
At cycle 3, 4 and 5 at day 5 : Re-injection of stem cells (1/3 with minimum 2.106 CD34/kg) 48 hours after chemotherapy end</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Germ cell tumors whatever histology (TGNS or séminoma : TGS ) whose origin is gonadic,&#xD;
             extra-gonadic, retro-peritoneal or primitive mediastinal&#xD;
&#xD;
          2. Age &gt;= 18 years old&#xD;
&#xD;
          3. Histologically confirmed germ cell tumor (TGS) or biomarkers rate allowing to diagnose&#xD;
             germ cell tumor without histology (TGNS)&#xD;
&#xD;
          4. Relapse or progression with bad prognosis in 1st treatment line : One of these&#xD;
             criteria valid point 4 :&#xD;
&#xD;
             progression after incomplete clinical response (Stable disease) to a Cisplatin basis&#xD;
             chemotherapy; biomarker progression 4 weeks following the last chemotherapy cycle&#xD;
             administration; progression during the first treatment line without obtention of at&#xD;
             least stable disease; primitive mediastinal origin in first relapse.&#xD;
&#xD;
          5. TGNS or TGS in relapse after 2 treatment lines&#xD;
&#xD;
          6. Disease progression ( previous points 4 or 5) documented by :&#xD;
&#xD;
             tumors biomarkers increase (AFP and/or HCG) if no, a biopsy is needed to confirm&#xD;
             presence of tumors active cells&#xD;
&#xD;
          7. ECOG Performance status 0-2&#xD;
&#xD;
          8. Biological Function :&#xD;
&#xD;
             Neutrophils &gt;= 1500/mm3, Platelets &gt;= 150.000/mm3 ; normal creatinine (or clearance &gt;=&#xD;
             50 ml/mn) ; SGOT, SGPT &lt;= 2,5N (or 5N if hepatic metastases), Bilirubin &lt; 1,5N&#xD;
&#xD;
          9. Cardiac Functions (FEV &gt;= 50%), Respiratory Functions , neurological Functions&#xD;
             compatibles with high dose chemotherapy administration&#xD;
&#xD;
         10. Absence of previous intensification&#xD;
&#xD;
         11. Patient Information and Informed consent signature&#xD;
&#xD;
         12. HIV and B and C hepatitis negative serologies&#xD;
&#xD;
         13. Negative pregnancy test for women with reproductive potential and adequate&#xD;
             contraception before study entry&#xD;
&#xD;
         14. Patient affiliated to social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients whose diagnosis of relapse was not confirmed by an anatomopathological&#xD;
             examination or by an increase of tumors markers&#xD;
&#xD;
          2. Primitive encephalic germ cell tumors&#xD;
&#xD;
          3. Germ cell tumors in relapse with favorable factors of treatment response to&#xD;
             conventional chemotherapy (RC sustainable after Cisplatin): prior cRC or incomplete&#xD;
             clinical response but with normalization of markers and testicular origin&#xD;
&#xD;
          4. Growing Teratoma lesions&#xD;
&#xD;
          5. Patients with HIV infection, hepatitis B and C&#xD;
&#xD;
          6. Patients with symptomatic brain metastases despite appropriate corticosteroid&#xD;
             treatment&#xD;
&#xD;
          7. Associated pathology may prevent the patient to receive treatment, creatinine&#xD;
             clearance ≤ 50 mL / min (calculated by Cockcroft-Gault)&#xD;
&#xD;
          8. FEV &lt;50%&#xD;
&#xD;
          9. History of cancer (except basal cell epithelioma skin cancer) in the 3 years preceding&#xD;
             the entry into the trial&#xD;
&#xD;
         10. Patient already included in another clinical trial involving an experimental molecule&#xD;
&#xD;
         11. Pregnant or breast feeding women&#xD;
&#xD;
         12. Persons without liberty or under guardianship,&#xD;
&#xD;
         13. Geographical, social or psychological conditions that do not permit compliance with&#xD;
             protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine CHEVREAU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Claudius Regaud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital St André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Val d'aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06050</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital TENON</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 16, 2009</study_first_submitted>
  <study_first_submitted_qc>March 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2009</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory</keyword>
  <keyword>germ cell tumors</keyword>
  <keyword>relapse</keyword>
  <keyword>bad prognosis</keyword>
  <keyword>Refractory germ cell tumors with relapse and bad prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

